NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Get Free Report) rose 2.6% during mid-day trading on Wednesday . The company traded as high as $3.50 and last traded at $3.10. Approximately 39,253 shares changed hands during trading, a decline of 96% from the average daily volume of 1,065,755 shares. The stock had previously closed at $3.02.
NeuroBo Pharmaceuticals Trading Up 2.6 %
The stock’s fifty day moving average is $4.51 and its 200-day moving average is $3.97.
NeuroBo Pharmaceuticals Company Profile
NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.
Further Reading
- Five stocks we like better than NeuroBo Pharmaceuticals
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- High-Yield Texas Instruments Could Hit New Highs Soon
- What is the Australian Securities Exchange (ASX)
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Using the MarketBeat Stock Split Calculator
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
